CTOP TFA,99.93%

产品编号:Bellancom-P1329A| 分子式:C52H68F3N11O13S2| 分子量:1176.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-P1329A
2500.00 杭州 北京(现货)
Bellancom-P1329A
7500.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

CTOP TFA

产品介绍 CTOP TFA 是一种有效的、高选择性的 μ- 阿片受体 (μ-opioid receptor) 拮抗剂。CTOP TFA 可拮抗吗啡诱导的急性镇痛作用和运动亢进。CTOP TFA 提高伏隔核的细胞外多巴胺水平。CTOP TFA 剂量依赖性增强运动能力。
生物活性

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity.

体外研究
体内研究

CTOP TFA (0-0.5 nmol, ICV, once) antagonizes the analgesic effect in a dose-dependent manner.
CTOP TFA (0-2 nmol, ICV, once) causes withdrawal hypothermia and a loss of body weight in animals.
CTOP TFA (0-1.5 nmol per side, Intra-VTA injection) enhances extracellular dopamine levels in the nucleus accumbens and dose-dependently enhances locomotor activity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male CFLP mice (25-30 g)
Dosage: 0, 0.001, 0.05, 0.075, 0.1, and 0.5 nmol (made up in artificial cerebrospinal fluid (CSF) and kept in plastic tubes at -25℃ until use)
Administration: Intracerebroventricular (i.c.v.) administration, once
Result: Antagonized the analgesic effect in a dose-dependent manner, antagonized the induced hypermotility in a dose-dependent manner.
Animal Model: Male CFLP mice (25-30 g, Acute dependence to morphine was induced by a single dependence-inducing (100 mg/kg) dose of morphine-HC1)
Dosage: 0, 0.001, 0.05, 0.2, and 2 nmol
Administration: Intracerebroventricular (i.c.v.) administration, once
Result: Decreased the body temperature in a dose-dependent manner, and caused withdrawal hypothermia and a loss of body weight in animals.
Animal Model: Long-Evans hooded rats (12, male, 350-450 g)
Dosage: 0, 0.015, 0.15, and 1.5 nmol per side
Administration: Intra-VTA (ventral tegmental area) injection
Result: Enhanced extracellular dopamine levels in the nucleus accumbens, dose-dependently increased activity, whereas had no effect on feeding and drinking behavior.
体内研究

CTOP TFA (0-0.5 nmol, ICV, once) antagonizes the analgesic effect in a dose-dependent manner.
CTOP TFA (0-2 nmol, ICV, once) causes withdrawal hypothermia and a loss of body weight in animals.
CTOP TFA (0-1.5 nmol per side, Intra-VTA injection) enhances extracellular dopamine levels in the nucleus accumbens and dose-dependently enhances locomotor activity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male CFLP mice (25-30 g)
Dosage: 0, 0.001, 0.05, 0.075, 0.1, and 0.5 nmol (made up in artificial cerebrospinal fluid (CSF) and kept in plastic tubes at -25℃ until use)
Administration: Intracerebroventricular (i.c.v.) administration, once
Result: Antagonized the analgesic effect in a dose-dependent manner, antagonized the induced hypermotility in a dose-dependent manner.
Animal Model: Male CFLP mice (25-30 g, Acute dependence to morphine was induced by a single dependence-inducing (100 mg/kg) dose of morphine-HC1)
Dosage: 0, 0.001, 0.05, 0.2, and 2 nmol
Administration: Intracerebroventricular (i.c.v.) administration, once
Result: Decreased the body temperature in a dose-dependent manner, and caused withdrawal hypothermia and a loss of body weight in animals.
Animal Model: Long-Evans hooded rats (12, male, 350-450 g)
Dosage: 0, 0.015, 0.15, and 1.5 nmol per side
Administration: Intra-VTA (ventral tegmental area) injection
Result: Enhanced extracellular dopamine levels in the nucleus accumbens, dose-dependently increased activity, whereas had no effect on feeding and drinking behavior.
性状Solid
溶解性数据
In Vitro: 

H2O : 50 mg/mL (42.51 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.8501 mL 4.2507 mL 8.5014 mL
5 mM 0.1700 mL 0.8501 mL 1.7003 mL
10 mM 0.0850 mL 0.4251 mL 0.8501 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 100 mg/mL (85.01 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服